C
Can-Fite BioPharma Ltd D
D
CANF
1.08500
USD
0.04
(3.83%)
مغلق
حجم التداول
180
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
13,945,600
الأخبار المقالات
العنوان: Can/Fite BioPharma Ltd
القطاع: Healthcare
الصناعة: Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).